Boards of Directors

Global Board of Directors

Karen Etchberger, CSL Behring - Chair
David Bell, Grifols
David Gao, Bio Products Laboratory
Julie Kim, Takeda
Paolo Marcucci, Kedrion SpA
Michael Ramroth, Biotest AG

Europe Board of Directors

Oliver Schmitt, CSL Behring GmbH - Chair
Michael Mensa, Bio Products Laboratory
Thierry Heinrich, Grifols Deutschland GmbH
Roberto Tana, Kedrion
Eric Thomas, Biotest
Rob de With, Takeda

North America Board of Directors

Bill Zabel, Grifols - Chair
Lynda Bowe, Kedrion Biopharma, Inc.
Adam Grossman, ADMA Biologics, Inc.
Bob Lojewski, CSL Behring
Brandon Monk, Takeda
Bob Rossilli, Bio Products Laboratory
Laura Saward, Emergent BioSolutions Inc.

Source Board of Directors

Roger Brinser, Takeda/BioLife - Chair
Peter Allen, Grifols Plasma Operations
Jay Bae, GCAM, Inc.
Bill Bees, Prometic Plasma Resources
Allen Coleman, CSL Plasma
Marvin Dyke, BPL Plasma
Milan Maly, UNICAplasma s.r.o.
Rudolf Meixner, PlasmaVita Healthcare GmbH
Paolo Melloni, Kedrion
David Morad, Southern Blood Services
Dr. Martin Reinecke, Biotest AG

PPTA News

Inception Impact Assessment Underlines the Need for Timely Action to Decrease the Reliance on Third Countries for Plasma +

The Plasma Protein Therapeutics Association (PPTA) welcomes the European Commission’s publication of the Inception Impact Assessment (IIA) as a necessary step in the ongoing evaluation of the EU legislation on blood, tissues, and cells (BTC). Rightfully, the assessment underlines the need for timely action to decrease Europe’s reliance on third countries for plasma. We appeal to authorities to urgently take the necessary steps to collect more plasma through plasmapheresis in Europe As highlighted by the European Commission, plasmapheresis is a more efficient collection method compared to the collection of recovered plasma.¹
Read More
PPTA Statement on the Urgent Need for Plasma Donation +

COVID-19 continues to present a prolonged, global public health emergency, but PPTA remains steadfastly committed to its mission to promote the availability of — and access to — safe and effective plasma protein therapies for all patients. PPTA member companies operate more than 1,000 Source plasma donation centers in the U.S. and four countries in the European Union and manufacture plasma-derived therapies that treat patients with serious, rare, and often genetic diseases and disorders, including: primary immune deficiencies, bleeding disorders, Alpha-1 Antitrypsin deficiency, hereditary angioedema, and certain neurological conditions. These conditions are often only treated with therapies produced from plasma.
Read More
Plasma Donors Should be Celebrated, not Denigrated +

The Guardian published an editorial on October 21 by Arwa Mahdawi that relies heavily on a 2015 article that intentionally sought to perpetuate a divisive representation of plasma donors’ commitments and motivations – Ms. Mahdawi used those negative insinuations in a broader attempt to castigate the U.S. and its public support programs. The Plasma Protein Therapeutics Association (PPTA) and its member companies are grateful for every plasma donor, each of whom directly contributes to saving and improving the lives of people facing serious, inherited, and life-threatening diseases.
Read More
International Plasma Awareness Week 2020: Be a Hero, Donate Plasma Today +

ANNAPOLIS, MD (October 5, 2020) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the eighth annual International Plasma Awareness Week (IPAW), which will run until October 9.
Read More

1
2
3

› ‹

Mission Video

Learn more about the need for plasma donors, plasma donation, and how you can save and improve lives. Find a Donation Center.

"How Is Your Day?" is an initiative to raise awareness of the unique nature of plasma protein therapies and the value they provide to patients. It aims to inform and educate decision makers and the general public worldwide.

Get involved and follow "How Is Your Day?" on social media @HIYDglobal

Media and Information

Advocacy

Copyright © 2020 PPTA. All rights reserved. (202) 789-3100

Terms of Use | Privacy Statement | Sitemap